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ABSTRACT: Genetic screening in Alzheimer’s disease (AD) has identified
only a handful of genes that are mutated in the disorder. Thus, for a very
large proportion of patients, the biology of their disease is poorly under-
stood. Epigenetic alterations may provide an explanation in these cases.
Using DNA methylation profiles of human hippocampus from controls and
patients, we have identified the presence of promoter hypermethylation of
the dual-specificity phosphatase 22 (DUSP22) gene in AD. DUSP22 is a
likely candidate gene for involvement in the pathogenesis of the disorder
since, as we demonstrate here, it inhibits PKA activity and thereby deter-
mines TAU phosphorylation status and CREB signaling.VC 2014 The Authors.
Hippocampus Published by Wiley Periodicals, Inc.
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Alzheimer’s disease (AD) is the most frequent degener-
ative brain disorder in western society. It affects 11% of
people older than 65 years and 50% of those older than
85 years. It is characterized by a progressive decline in
mental abilities, neuronal loss and accumulation of amy-
loid plaques and neurofibrillary tangles of phosphoryl-
ated TAU (Querfurth et al., 2010). Epidemiologically,
there are two main variants of AD, a rare familial early-
onset variant, caused by mutations in amyloid precursor
protein (APP), presenilin 1 (PSEN1) or presenilin 2
(PSEN2), and a sporadic late-onset variant, representing
95% of cases and for which only one gene, APOE, has
been clearly associated as a risk factor (Querfurth et al.,
2010). In recent decades, attempts to discover new risk
factors for AD using genetic screening have not been as
successful as expected (Bertram et al., 2008). A consider-
ation of epigenetics offers additional opportunities to
identify disease-associated genes. In this context, initial
epigenetic screening has already identified genes that are
deregulated by DNA methylation in case-control studies
of AD (Seigmund et al., 2009; Bakulski et al., 2012; Rao
et al., 2012). Herein, we focus our attention on the DNA
methylation profile in one of the brain regions most
commonly affected in AD, the hippocampus.
We compared the DNA methylation status of
27,578 individual CpG sites corresponding to 14,475
unique genes (Bibikova et al., 2009) in five DNA
samples of control hippocampus grey matter, five
Braak stage I–II, five Braak stage III–IV, and five
Braak stage V–VI DNA samples from sporadic late-
onset AD cases (Supporting Information). The avail-
able clinicopathological information (Braak staging,
age, and gender) for the control samples in this dis-
covery cohort is described in Supporting Information.
To detect sites that are differentially methylated in
AD, we selected those CpGs that yielded a more than
25% average beta-value difference between controls
and Braak stage V–VI samples with increasing CpG
methylation differences according to their Braak stage.
The DNA methylation data obtained are freely avail-
able in the Gene Expression Omnibus database:
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=
ttmzxyksmukiafk&acc=GSE45775.
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Using this approach, four CpG methylation probes corre-
sponding to three individual genes showed a significant differ-
ence (Mann–Whitney test, FDR adjusted P < 0.05): dual-
specificity phosphatase 22 (DUSP22), claudin 15 (CLDN15),
and quiescin Q6 sulfhydryl oxidase 1 (QSCN6). DUSP22 is
represented by two CpG probes that are differentially methyl-
ated between control and AD samples (Fig. 1a). There was a
linear relationship between DUSP22 methylation and the
Braak stage (Pearson correlation coefficient R 5 0.95, P <
0.05) (Supporting Information). In addition, because cogni-
tively normal controls above age 80 might also have Braak I &
II, we pooled these samples with the five AD Braak stage I–II
samples as our reference population. Using this approach, the
two DUSP22 CpG probes retained the highest differences
between the reference population and the pooled AD Braak
stage III-IV-V-VI group with a 13.5% and 12.7% DNA meth-
ylation difference. For all these reasons, we studied this candi-
date gene further for evidence of epigenetic dysregulation.
We next confirmed the presence of DUSP22 hypermethyl-
ation in the disease-associated DNAs using a different DNA
methylation detection technology (pyrosequencing) in an inde-
pendent set of 25 control hippocampus grey matter and 25
AD samples (Supporting Information and Fig. 1b). The avail-
able clinicopathological information (Braak staging, age, and
gender) for the control samples in this validation cohort is
described in Supporting Information. The lower methylation
difference found in the validation set in comparison to the dis-
covery set could be explained because the pyrosequencing data
is an average across a larger region that contains three CpGs
where only one is a critical CpG derived from the DNA meth-
ylation microarray. We observed downregulation of the
DUSP22 RNA transcript (0.67 6 0.07 fold change; t-test P <
0.05) (Fig. 1b) and protein (0.50 6 0.07 fold change; t-test
P < 0.05) (Fig. 1c) in the AD hippocampus samples compared
with the control tissues. In keeping with the accepted epige-
netic concept that links gene promoter hypermethylation and
transcriptional inactivation (Portela et al., 2010), we observed a
correlation between DUSP22 DNA methylation and dimin-
ished RNA expression (R2 5 0.23, P < 0.05) (Fig. 1d).
Once we had identified the presence of DUSP22 promoter
hypermethylation and downregulation in the hippocampus of
AD patients, we examined its potential functional consequen-
ces. Dual-specific phosphatases (DUSPs) can dephosphorylate
both tyrosine and serine/threonine residues (Patterson et al.,
2009). DUSP22, also known as JNK pathway-associated phos-
phatase (JKAP), is expressed in various types of tissues and
organs (Chen et al., 2009), including the hippocampus
(Hawrylycz et al., 2012), suggesting that it may participate in
essential biological processes. The TAU protein could be an
important target for DUSP22-mediated dephosphorylation in
AD. TAU Thr231 phosphorylation is one of the first phospho-
rylation events in AD and has a major role in TAU regulation
(Luna-Mu~noz et al., 2007). Although phosphoseryl/phospho-
threonyl protein phosphatase-2A (PP-2A) appears to be the
most active enzyme in dephosphorylating the abnormal TAU
to a near-normal state (Wang et al., 2013), other phosphatases
might also play a role. Due to the lack of human cell culture
models of AD, we screened a panel of seven cell lines from
neuronal lineages (the neuroblastoma cell lines SH-SY5Y, SK-
N-AS, SK-N-BE(2), SK-N-F1, SKN-JD, and SK-N-SH) for
TAU Thr231 phosphorylation (Fig. 2a). In this setting, SK-N-
BE(2) presented the highest levels of TAU Thr231 phosphoryl-
ation (Fig. 2a) and was selected for further experimentation.
Stable short-hairpin RNA (shRNA) depletion of DUSP22 in
FIGURE 1. DUSP22 promoter hypermethylation and dimin-
ished expression in hippocampus of AD patients. (a) Schematic rep-
resentation of DUSP22 promoter. CpGs interrogated by microarray
and pyrosequencing are represented by grey and black stars, respec-
tively. Vertical lines represent CpG dinucleotides. (b) Left, DNA
methylation in control and AD samples measured by pyrosequenc-
ing. Mean values for three CpGs are shown. Right, fold change in
RNA expression between control and AD samples. (c) DUSP22 pro-
tein levels in control and AD samples measured by western blot. (d)
Correlation of DUSP22 DNA methylation and RNA expression.
*P < 0.05 in two-tailed Student’s t-test. Correlation p-value corre-
sponds to the linear regression coefficient.
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SK-N-BE(2) cells caused a loss of TAU Thr231 phosphoryla-
tion in comparison with the shRNA scramble cells (Fig. 2b).
In the reciprocal experiment we found the equivalent result,
whereby stable transfection of DUSP22 in SK-N-BE(2) cells
caused an increase in TAU Thr231 phosphorylation (Fig. 2c).
These data suggest that DUSP22 affects TAU Thr231 phos-
phorylation status but in an inverse manner, contrary to what
was expected. Thus, TAU is not itself a direct target of
DUSP22, but its phosphorylation depends indirectly on the
studied phosphatase.
Several candidates could mediate the effect of DUSP22 on
TAU phosphorylation, the most likely targets being those
kinases that phosphorylate TAU. In this regard, we studied the
glycogen synthase kinase 3 (GSK3b), p38 mitogen-activated
protein kinase (p38) and cAMP-dependent protein kinase
(PKA) proteins which are all able to phosphorylate TAU at the
Thr231 site (Wang et al., 2013). The use of a GSK3b inhibi-
tor (lithium) caused a similar reduction of TAU Thr231 phos-
phorylation in both DUSP22 shRNA-depleted (0.7 6 0.12)
and transfected SK-N-BE(2) (0.5 6 0.13) cells (Fig. 2d). In a
similar way, the use of a p38 activator (sorbitol) induced a sim-
ilar increase in TAU Thr231 phosphorylation in both
DUSP22 experimental models, stable downregulation (2.7 6
0.5) and stable overexpresssion (2.2 6 0.6) (Fig. 2d). These
findings suggest that the two TAU Thr231 phosphorylation
pathways are unaffected by DUSP22 expression. A different
pattern was observed for PKA, wherein the use of the PKA
activator forskolin was able to induce TAU Thr231 phospho-
rylation in DUSP22 shRNA-depleted cells (2.2 6 0.5), but
not in DUSP22-overexpressing SK-N-BE(2) cells (0.8 6 0.3)
(Fig. 2d). This result suggests that DUSP22 inhibits PKA
activity, and the link between the two pathways was confirmed
by the observation that both proteins are located in the cellular
membrane subfraction (Fig. 2e) and co-immunoprecipitate
(Fig. 2e).
PKA has a complex regulation in which two catalytic and two
regulatory subunits are differentially associated and phosphoryl-
ated (Taylor et al., 2012). In response to cAMP production,
PKA regulatory subunits release the catalytic components which
are concomitantly phosphorylated at Thr197 constituting the
active form of the enzyme (Taylor et al., 2012). DUSP22 shRNA
depletion increased PKA Thr197 phosphorylation, while
FIGURE 2. DUSP22 regulates TAU phosphorylation through
PKA. (a) Levels of TAU Thr231 phosphorylation across different
neuronal cell lines. (b) Stable clones interfering (top) and overex-
pressing (bottom) DUSP22. (c) Levels of TAU Thr231 phosphoryla-
tion across stable clones. (d) Levels of TAU Thr231 phosphorylation
between interfered and overexpressing DUSP22 SK-N-BE(2) cells
after 24 h of 20 mM LiCl, 30 min of 500 mM sorbitol and 30 min
of 50 mM forskolin treatments. (e) Top, immunoprecipitation
between DUSP22-myc tagged and catalytic subunits of PKA. Below,
western blot to confirm cellular fractionation using membrane
(AKAP79), cytosol (NSE) and nuclear (Histone H3) located pro-
teins. (f ) Basal levels of PKA Thr197 of wild-type, scramble, inter-
fered and overexpressing DUSP22 SK-N-BE(2) cells.
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DUSP22 transfection decreased phosphorylation. Wild-type and
shRNA scramble cells showed intermediate phosphorylation
(Fig. 2f ). These data reinforce the idea of DUSP22 acting as a
PKA inhibitor.
In addition to the DUSP22 role on PKA-mediated TAU
phosphorylation, the epigenetic silencing of the studied phos-
phatase can have another physiopathological role in PKA and
the disease: its impact on the cAMP response element-binding
protein (CREB) signaling pathway. CREB activity is nowadays
considered critical for neuronal function and regulates synaptic
plasticity, long-term memory formation and neuronal survival
(Lonze et al., 2002); all processes that are altered in AD (Quer-
furth et al., 2010). Given that PKA activates CREB by phos-
phorylation of Ser133 (Johannessen et al., 2004), we analyzed
this pathway in our model. We found that in SK-N-BE(2) cells
with stable overexpression of DUSP22 the phosphorylation of
CREB Ser133 upon the use of the PKA activator was delayed
relative to DUSP22-shRNA-depleted cells (Fig. 3a). Most sig-
nificantly, we also observed that DUSP22 through PKA was
able to regulate the expression of CREB target downstream
genes, such as somatostatin (SST), nuclear receptor subfamily 4
group member 2 (NR4A2) and FBJ osteosarcoma oncogene
(FOS). We found that in DUSP22-shRNA-depleted cells the
use of the PKA activator induced the expression of the
described CREB-response genes in comparison with the lack of
effect in DUSP22 stable transfected cells (Fig. 3b). With
respect to the CREB target genes, the effect on SST is of par-
ticular note because its expression is a protective factor against
amyloid beta (Ab) toxicity (Rubio et al., 2012). In this regard,
we were able to show that DUSP22-shRNA-depleted cells have
a significantly higher survival ability (measured by the MTT
assay) than the cells with stable overexpression of DUSP22
(Fig. 3c). Most importantly, the external addition of STT in
the DUSP22-overexpressing cells can partially rescue the sur-
vival ability of these cells upon Ab use (Fig. 3c), providing evi-
dence of the role of STT as a neuroprotective factor and the
contribution of DUSP22 to these processes. Thus, these latter
data imply that the inhibition of PKA by DUSP22 also causes
a loss of CREB phosphorylation and of the activity that affects
its downstream effector genes and functions, such as STT and
cell survival.
DUSP22, VHR-related MKPX (VHX), JNK stimulatory
phosphatase-1 (JSP-1), and LMW-DSP2 are members of the
atypical dual specificity phosphatases family (DUSPs); these
small proteins lack the typical N-terminal regulatory domain of
DUSPs proteins. DUSPs are important signaling regulators
that dephosphorylate tyrosine and serine/threonine residues and
can act on many substrates (Patterson et al., 2009). Herein, we
have demonstrated that DUSP22 is epigenetically deregulated
in AD and that it affects PKA signaling in neuroblastoma cells.
Our results suggest that DUSP22 expression could elicit a
handicap in PKA/GSK3b regulation and TAU phosphoryla-
tion. Furthermore, this suggests that high-expressing DUSP22
cells would have a special tendency to accumulate hyperphos-
phorylated TAU, thereby reducing the viability of such cells.
Therefore, the increase in DNA promoter methylation in
DUSP22 observed in AD could be consequence of an imbal-
ance of cell populations, by which high DUSP22-expressing
cells would persistently dwindle in parallel with the progression
of the disease, and only epigenetically-silenced DUSP22 cells
would remain viable. We cannot reject the possibility that cells,
in order to increase their survival, actively methylate DUSP22
promoter when exposed to Ab-induced toxicity. Nevertheless,
it highlights the role of PKA/GSK3b signaling in AD and sup-
ports the idea that treatments inducing DUSP22 inhibition
could benefit AD patients.
Additionally, our results suggest that DUSP22 expression
could also compromise Ab-induced cell survival through PKA/
CREB inhibition outstanding the pro-survival role of the down-
stream SST gene. Complete disruption of CREB is lethal
FIGURE 3. DUSP22 regulates CREB phosphorylation and
activity through PKA. (a) Different kinetics of CREB activation
between interfered and overexpressing DUSP22 SK-N-BE(2) cells
measured by Ser133 phosphorylation. (b) RNA expression patterns
of genes downstream CREB wild type, interfered and overexpressing
DUSP22 SK-N-BE(2) cells after 2 h of 50 mM forskolin treatment.
(c) Percentage cell survival after 24 h of 50 mM Ab treatment in wild
type, interfered and overexpressing DUSP22 SK-N-BE(2) cells with
and without external addition of 25 mM SST peptide measured by
MTT assay. *P < 0.05 in two-tailed Student’s t-test.
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(Rudolph et al., 1998), but its partial disturbance has been asso-
ciated to several neurological disorders. Coffin-Lowry syndrome
and Rusbenstein-Taybi Syndrome are caused by mutations in
CREB pathway genes (Petrij et al., 1995; Trivier et al., 1996).
CREB signaling deficits have also been reported in Huntington’s
disease (Steffan et al., 2000), Parkinson’s disease (Andersson
et al., 2001) and AD (Saura et al., 2011). Namely, much time
has passed since CREB was initially associated with AD in semi-
nal studies reporting a decrease of CREB phosphorylation in AD
(Yamamoto-Sasaki et al., 1999). Similarly, the AD Tg2756 mice
model also exhibits reduced CREB expression (Pugazhenthi
et al., 2011) and phosphorylation (Dineley et al., 2001), suggest-
ing a general disturbance of CREB signaling in AD. In fact, Ab
can impair PKA/CREB signaling at different levels. On one
hand, Ab decreases PKA activity and CREB phosphorylation
in hippocampal neurons (Vitolo et al., 2002). On the other
hand, Ab also inhibits CREB regulated transcription coactivator
1 (CRTC1) with similar results in CREB signaling (Espa~na
et al., 2010); in both cases, this resulted in reduced synaptic plas-
ticity and memory formation. Our data is in line with these
results and reinforce the idea that CREB signaling could be
affected in AD.
The importance of epigenetic alterations to our under-
standing of human disease is increasingly well established and
such changes are probably also involved in neurodegenerative
disorders, such as AD. Herein, we have shown that in the
hippocampus of AD patients a particular phosphatase
(DUSP22) undergoes promoter hypermethylation and loss of
expression. We further demonstrate that this enzyme could be
relevant, as a PKA inhibitor, in TAU phosphorylation and
CREB signaling, two pathways that are essential in AD path-
obiology. However, a limitation of the studies doing whole
tissue epigenetics, such as this one, derives from the recogni-
tion that the number of neurons in a hippocampus varies
wildly between Braak V and Braak I samples, thus the distinct
DNA methylation profiles could also be due to changing cell
type populations with disease, rather than a mechanism of
disease in neurons. These issues will be the focus of future
research in this area.
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